Melatonin suppresses cancer cell proliferation, DNA repair and expression of the oncogene TRIP13
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-28 07:44
摘要：
Melatonin has been identified as a promising therapeutic agent for non-small cell lung cancer (NSCLC) by downregulating the oncogene TRIP13, which is linked to cancer cell proliferation and DNA repair mechanisms. The study demonstrates that melatonin not only inhibits the growth of NSCLC cells but also enhances the effectiveness of TRIP13 inhibitors, suggesting a potential combination therapy approach. Furthermore, high TRIP13 expression correlates with poor patient prognosis, highlighting its significance as a therapeutic target in lung cancer treatment.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
Melatonin downregulates TRIP13, inhibiting NSCLC cell proliferation.
Combination of melatonin and TRIP13 inhibitor shows enhanced anti-proliferative effects.
TRIP13 expression correlates with poor prognosis in lung cancer patients.
真实性检查
否
AI评分总结
Melatonin has been identified as a promising therapeutic agent for non-small cell lung cancer (NSCLC) by downregulating the oncogene TRIP13, which is linked to cancer cell proliferation and DNA repair mechanisms. The study demonstrates that melatonin not only inhibits the growth of NSCLC cells but also enhances the effectiveness of TRIP13 inhibitors, suggesting a potential combination therapy approach. Furthermore, high TRIP13 expression correlates with poor patient prognosis, highlighting its significance as a therapeutic target in lung cancer treatment.